drugset / Trial / NCT07347288
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
Phase 2
Not yet recruiting
30 enrolled
The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the Safety and Efficacy of SHR2554 as Maintenance Therapy after first-line systemic treatment in patients with peripheral T-cell lymphoma
Timeline
- Start
- 2026-02
- Primary completion
- 2029-02
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR2554 | Small molecule | — | Oral |
Indications
No indication recorded.